Nova Eye Medical Ltd
ASX:EYE

Watchlist Manager
Nova Eye Medical Ltd Logo
Nova Eye Medical Ltd
ASX:EYE
Watchlist
Price: 0.17 AUD 6.25% Market Closed
Market Cap: AU$48.4m

Nova Eye Medical Ltd
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nova Eye Medical Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Nova Eye Medical Ltd
ASX:EYE
Research & Development
-AU$2.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Somnomed Ltd
ASX:SOM
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cyclopharm Ltd
ASX:CYC
Research & Development
-AU$443.9k
CAGR 3-Years
6%
CAGR 5-Years
37%
CAGR 10-Years
-36%
Cochlear Ltd
ASX:COH
Research & Development
-AU$299.9m
CAGR 3-Years
-12%
CAGR 5-Years
-11%
CAGR 10-Years
-8%
Austco Healthcare Ltd
ASX:AHC
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
EMvision Medical Devices Ltd
ASX:EMV
Research & Development
-AU$4m
CAGR 3-Years
-20%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Nova Eye Medical Ltd
Glance View

Market Cap
48.4m AUD
Industry
Health Care

Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia and currently employs 130 full-time employees. The firm is focused on developing, manufacturing and selling a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), which is a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patients' reliance on anti-glaucoma medications for mild-moderate glaucoma. Its Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma. The firm's 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD).

EYE Intrinsic Value
0.18 AUD
Undervaluation 4%
Intrinsic Value
Price

See Also

What is Nova Eye Medical Ltd's Research & Development?
Research & Development
-2.7m AUD

Based on the financial report for Jun 30, 2025, Nova Eye Medical Ltd's Research & Development amounts to -2.7m AUD.

Back to Top